Updated ASCO guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit with the Oncotype DX Breast Recurrence Score® test in node-negative breast cancer Press Release
One Year Post-TAILORx: Attitudes Shift and Questions Linger in Breast Cancer Recurrence Testing GenomeWeb (requires free registration)
Using Genomic Profiling to Guide Treatment Decisions for ER-Positive Breast Cancers, by Harold J. Burstein, MD, PhD CancerNetwork
New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer The ASCO Post
Arm H finds the combination of dabrafenib and trametinib effective in a heavily pre-treated cohort of 17 distinct tumor types–several rare–with BRAF mutations Press Release
Keith Flaherty, MD, ECOG-ACRIN study chair, comments on targeted drugs in an article on basket trials published in Xconomy National
Final results show no benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Press Release
ASCO 2019: Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with Metastatic Renal Cell Carcinoma who have no Evidence of Disease Following Metastasectomy – Medical Oncologist Perspective UroToday
No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Medical Xpress
Final results demonstrate that lenalidomide reduces the risk that precancer myeloma will progress to overt multiple myeloma in high-risk individuals Press Release
“Why I choose to play a dual role in TMIST” by Worta McCaskill-Stevens, Division of Cancer Prevention, National Cancer Institute, in The Cancer Letter More Here
“Are we further reducing breast cancer mortality the more intensively we screen?” Conversation with The Cancer Letter and TMIST study chair Etta Pisano, MD More Here
Group Meeting Highlights
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD Group Co-Chair
Mitchell D. Schnall, MD, PhD Group Co-Chair
The ECOG-ACRIN Cancer Research Group has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN).